Bangalore, India | July 14, 2025 – Indegene, a digital-first life sciences commercialization company, has announced the launch of NEXT Medical Writing Automation — an advanced AI-powered platform set to redefine how high-quality, regulatory-compliant documents are created across clinical development and regulatory submissions.
✅ Solving the Pressure in Medical Writing
Medical writing teams in the life sciences sector face increasing pressure to deliver accurate, regulatory-ready contentunder tight timelines — all while handling fragmented data and changing compliance demands.
NEXT Medical Writing Automation addresses these pain points by merging:
- Decades of medical writing expertise
- Generative AI (GenAI) capabilities
- Indegene’s proprietary AI engine, Cortex
⚙️ Powered by Cortex: A Domain-Specific AI Engine
Cortex by Indegene is a life sciences-specialized knowledge engineering platform that ensures:
- Enterprise-grade governance
- Multi-agent orchestration
- Seamless integration with sponsor formats and workflows
NEXT Medical Writing Automation works within familiar tools like Microsoft Word, auto-generating compliant drafts while preserving traceability and format consistency. It also integrates with Regulatory Information Management (RIM) systems, making cross-document harmonization effortless.
🔄 From Draft to Delivery – Faster, Smarter, and Compliant
Key platform features include:
- Automated scheduling
- Intelligent task assignment
- Integrated data flow
- Compliance-centric design
This results in faster document creation, allowing medical writers to focus on strategic insights rather than manual formatting.
“We see this platform as more than automation — it’s about elevating the entire practice of medical writing,”said Sameer Lal, SVP, Enterprise Medical Solutions at Indegene.
🌐 A Stronger Global Offering with Trilogy Acquisition
This launch builds on Indegene’s acquisition of Trilogy Writing & Consulting GmbH in 2024 — a leading global medical writing company. The combination strengthens Indegene’s ability to:
- Support global market authorization submissions
- Deliver comprehensive medical writing services across clinical, regulatory, safety, and medical communications
🧬 About Indegene
Indegene Limited (BSE: 544172, NSE: INDGN) is a global, digital-first partner for life sciences companies. It supports biopharma, biotech, and medtech companies through every stage of the product life cycle — from development to commercialization.
🔗 Learn more: www.indegene.com
